Clinical implications and management of bleeding events in patients with acute coronary syndromes

Journal of Cardiovascular Medicine

Volumn 10, Issue 9, 2009, Pages 677-686

  De Luca, Leonardo ^a   Casella, Gianni ^b   Lettino, Maddalena ^c   Fradella, Giuseppe ^d   Toschi, Vincenzo ^e   Conte, Maria Rosa ^f   Ottani, Filippo ^g   Geraci, Giovanna ^h   Visconti, Luigi O ^c   Tubaro, Marco ⁱ   Maggioni, Aldo P ^j  

^a EUROPEAN HOSPITAL   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e SAN CARLO BORROMEO HOSPITAL   (Italy)

^f OSPEDALE DEGLI INFERMI   (Italy)

^g MORGAGNI PIERANTONI HOSPITAL   (Italy)

^h VILLA SOFIA CERVELLO HOSPITAL   (Italy)

ⁱ SAN FILIPPO NERI HOSPITAL   (Italy)

^j ANMCO RESEARCH CENTER   (Italy)

more..

Author keywords

Acute coronary syndromes; Antithrombotic agents; Bleeding; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; TENECTEPLASE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; FALSE ANEURYSM; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HUMAN; INCIDENCE; INFECTION; LOW DRUG DOSE; MORTALITY; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; THROMBOCYTOPENIA; VASCULAR ACCESS;

ACUTE CORONARY SYNDROME; BLOOD TRANSFUSION; DRUG MONITORING; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; INCIDENCE; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 68249154903     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283299808     Document Type: Review

References (76)

1. Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Brindis RG, et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 2006; 166:2027-2034. (Pubitemid 44537186)
2. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23:1190-1201. (Pubitemid 35215245)
3. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, et al., Euro Heart Survey Investigators. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006; 27:2285-2293.
4. Di Chiara A, Chiarella F, Savonitto S, Lucci D, Bolognese L, De Servi S, et al., BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003; 24:1616-1629.
5. Di Chiara A, Fresco C, Savonitto S, Greco C, Lucci D, Gonzini L, et al., BLITZ-2 Investigators. Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. Eur Heart J 2006; 27:393-405.
6. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, et al., GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007; 297:1892-1900.
7. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J 2008; 156 (2 Suppl):S3-S9.
8. Guagliumi G, Musumeci G, Rossini R, Bolognese L, Giordano A, Marzocchi A, et al. Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document. J Cardiovasc Med 2007; 8:782-791. (Pubitemid 47476415)
9. Bassand JP. Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm. Heart 2008; 94:661-666. (Pubitemid 351580149)
10. Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28:1193-1204. (Pubitemid 47343833)
11. Rao SV, Kaul PR, Liao L, Armstrong PW, Ohman EM, Granger CB, et al. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2008; 155:369-374.
12. Motivala AA, Tamhane U, Saab F, Li J, Rogers EK, Froehlich J, et al. Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications. Am J Cardiol 2007; 100:1359-1363. (Pubitemid 47576012)
13. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24:1815-1823.
14. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001; 286:708-713.
15. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, et al., for the CRUSADE Investigators. Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes. JAMA 2005; 294:3108-3116.
16. Wiviott SD, Braunwald E, McCabe CH,Montalescot G, Ruzyllo W, Gottlieb S, et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015.
17. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITONTIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51:2028-2033. (Pubitemid 351689056)
18. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al., Fifth Organization to Access Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464-1476.
19. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008; 52:807-814.
20. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al., Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203-2216.
21. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355:1006-1017. (Pubitemid 44343544)
22. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863. (Pubitemid 37430344)
23. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142-154.
24. The GUSTO I Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-682.
25. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47:809-816.
26. Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007; 154:3-11. (Pubitemid 46924806)
27. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998; 339:436-443.
28. The SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45-54.
29. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 2004; 110:1202-1208. (Pubitemid 39202333)
30. Berkowitz SD, Stinnett S, Cohen M, Fromell GJ, Bigonzi F. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-STsegment elevation acute myocardial infarction. Am J Cardiol 2001; 88:1230-1234. (Pubitemid 33132089)
31. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. The relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292:1555-1562. (Pubitemid 39314961)
32. Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, López- Sendón J, et al. GRACE Investigators. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of lowmolecular- weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005; 26:2285-2293.
33. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114:774-782. (Pubitemid 44268228)
34. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96:1200-1206. (Pubitemid 41505393)
35. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111:2042-2049. (Pubitemid 40577898)
36. Reinecke H, Trey T, Wellmann J, Heidrich J, Fobker M, Wichter T, et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 2003; 24:2142-2150. (Pubitemid 37486534)
37. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández- Avilés F, et al. Guidelines for the diagnosis and treatment of non-STsegment elevation acute coronary syndromes. The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007; 28:1598-1660.
38. Subherwal S. The CRUSADE Bleeding Score to assess baseline risk of major bleeding in non-ST-segment elevation myocardial infarction. Oral Presentation at the 57th Annual Scientific Meeting of the American College of Cardiology; 29 March to 1 April 2008; Chicago, Illinois.
39. Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG, Canadian Acute Coronary Syndromes Registries Investigators. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005; 150:690-694 (Pubitemid 41396500)
40. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92:930-935. (Pubitemid 37214804)
41. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292:696-703. (Pubitemid 39062523)
42. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schömig A, Kastrati A. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions. Appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51:690-697. (Pubitemid 351221218)
43. Dauerman HL. Percutaneous coronary intervention pharmacology. From a triangle to a square. J Am Coll Cardiol 2008; 51:698-700.
44. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al., HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218-2230.
45. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49:1362-1368. (Pubitemid 46476844)
46. Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 2007; 116:2793-2801.
47. Welch HG, Meenhan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116:393-402.
48. Aster RH, Bougie DW. Drug induced immune thrombocytopenia. N Engl J Med 2007; 357:580-587.
49. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355:809-817.
50. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 2004; 164:1961-1964. (Pubitemid 39390551)
51. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002; 359:189-198. (Pubitemid 34113814)
52. Patel SC, Mody A. Cerebral hemorrhagic complications of thrombolytic therapy. Prog Cardiovasc Dis 1999; 42:217-233.
53. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008; 133 (6 Suppl):257S-298S. (Pubitemid 351892969)
54. Sila CA. Neurologic complications of vascular surgery. Neurol Clin N Am 1998; 16:9-20.
55. Brown DL, Topol EJ. Stroke complication percutaneous coronary revascularization. Am J Cardiol 1993; 72:1207-1209.
56. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA 1997; 278:2093-2098. (Pubitemid 28016233)
57. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 2001; 357:1905-1914.
58. Wong GC, Antman EM, Giugliano RP. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003; 289:331-342. (Pubitemid 36090107)
59. Ng FH, Wong SY, Lam KF, Chang CM, Lau YK, Chu WM, Wong BC. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol 2008; 103:865-871.
60. Chin MW, Yong G, Bulsara MK, Rankin J, Forbes GM. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol 2007; 102:2411-2416. (Pubitemid 47631776)
61. Liberopoulos EN, Elisaf MS, Tselepis AD, Archimandritis A, Kiskinis D, Cokkinos D, Mikhailidis DP. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets 2006; 17:1-6.
62. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 Expert Consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118:1894-1909.
63. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38:316-321. (Pubitemid 26074312)
64. Saeed ZA, Winchester CB, Michaletz PA, Woods KL, Graham DY. A scoring system to predict recurrent bleeding after endoscopic therapy of nonvariceal upper gastrointestinal haemorrhage, with a comparison of heat probe and ethanol injection. Am J Gastroenterol 1993; 88:1842-1849.
65. Vreeburg EM, Terwee CB, Snel P, Rauws EA, Bartelsman JF, Meulen JH, Tytgat GN. Validation of the Rockall risk scoring system in upper gastrointestinal bleeding. Gut 1999; 44:331-335. (Pubitemid 29119326)
66. Barada K, Karrowni W, Abdallah M, Shamseddeen W, Sharara AI, Dakik HA. Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors. J Clin Gastroenterol 2008; 42:368-372.
67. Rothman MT. Drug insight: bleeding after percutaneous coronary intervention -risks, measures and impact of anticoagulant treatment options. Nat Clin Pract Cardiovasc Med 2005; 2:465-474.
68. Kiemeneij F, Laarman GJ, Slagboom T, van der Wieken R. Outpatient coronary stent implantation. J Am Coll Cardiol 1997; 29:323-327.
69. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi M, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures. Systematic overview and metaanalysis of randomized trials. J Am Coll Cardiol 2004; 44:349-356. (Pubitemid 38950594)
70. Kiemeneij F, Laarman GJ, Odekerken D, Slagboom T, van der Wieken R. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol 1997; 29:1269-1275. (Pubitemid 27201945)
71. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287:324-327.
72. De Caterina R, Husted S, Wallentin L, Agnelli G, Bachmann F, Baigent C, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007; 28:880-913. (Pubitemid 47343588)
73. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27:647-654.
74. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113:e166-e286.
75. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1822-1834. (Pubitemid 350007957)
76. Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29:2877-2885.